Thor Halfdanarson, Vice President of the North American Neuroendocrine Tumor Society, posted the following on X:

“Struggling with response assessment in patients with NETs following PRRT…? If so, you are not alone. Check out this report from ENETS by Christophe Deroose, Justo Castano, Simona Glasberg, Hans Hofland, Angela Lamarca and others. Good stuff!”

Follow-up comment by Thor Halfdanarson:

“Interestingly, there was an agreement that interim (midpoint) imaging should be done in patients on PRRT, after the 2nd or 3rd cycle which has been my practice since I began offering PRRT. Just over 50% recommended combining SSTR PET w/ anatomical x-sectional imaging like CT/MRI.”

Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force

Authors: Vikas Prasad, Anna Koumarianou, Timm Denecke, Anders Sundin, Christophe M. Deroose, Marianne Pavel, Emanuel Christ, Angela Lamarca, Martyn Caplin, Justo P. Castaño, Clarisse Dromain, Massimo Falconi, Simona Grozinsky-Glasberg, Johannes Hofland, Ulrich Peter Knigge, Beata Kos-Kudla, Balkundi A. Krishna, Nicholas Simon Reed, Aldo Scarpa, Rajaventhan Srirajaskanthan, Christos Toumpanakis, Andreas Kjaer, Rodney J. Hicks, Valentina Ambrosini

Thor Halfdanarson: Struggling with response assessment in patients with NETs?

More posts featuring Thor Halfdanarson.